9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Estimated reading time: < 1 min

Condition: Advanced and/or Metastatic Solid Tumors

Estimated Enrollment: 96

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Number of treatment-emergent adverse events with INCMGA00012 in combination with chemotherapy,  Objective response rate (ORR),  Duration of response (DOR), Disease control rate (DCR)

Interventions: INCMGA00012, Gemcitabine

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: March 2021

Completion Date: September 2022

Last  Posted Date: August 7, 2019

Location: California Cancer Associates for Research and Excellence, Fresno, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT03920839

Was this article helpful?
Dislike 0